Tilray Brands, Inc.
Close on Oct 19, 2026
- Market cap
- $404.02M
- P/E (TTM)
- –
- Dividend yield
- –
About Tilray Brands
Medicinal Chemicals & Botanical Products, SIC 2833
Tilray Brands, Inc. is a consumer goods company operating in four segments: Beverage, Cannabis, Distribution, and Wellness. In beverage, it produces, markets, and sells craft beers, craft spirits, ready-to-drink beverages, ciders, and non-alcoholic drinks. Its cannabis segment cultivates, processes, and sells adult-use and medicinal cannabis products, including dried flower, pre-rolls, vapes, and edibles. Through its distribution and wellness businesses, the company distributes pharmaceutical products and manufactures hemp-based foods. Tilray supplies retail consumers, medical patients, doctors, hospitals, pharmacies, and commercial wholesalers.
Headquartered in Leamington and New York, the company operates in Canada, the United States, Europe, Australia, and Latin America. Tilray supplies medical cannabis to patients across more than twenty countries on five continents, with production facilities in Canada, Germany, and Portugal. Its beverage assets include seven production facilities, eighteen brewpubs, and a distillery in the United States, a brewery in Scotland, and thirty-five owned or franchised pubs across the United Kingdom, Ireland, and Australia.
Summary of the business section of Tilray Brands's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tilray Brands, Inc.
- Founded
- 2018
- Headquarters
- New York, NY
- Address
- 445 Park Avenue 10022
- Phone
- (519) 322-8800
- Website
- www.tilray.com
- Employees
- 3,595, May 31, 2026
- Industry
- Medicinal Chemicals & Botanical Products
- Fiscal year ends
- May 31
- Auditor
- PricewaterhouseCoopers LLP, Toronto, Canada
Stock & identifiers
- Ticker
- TLRY
- Exchange
- Nasdaq
- IPO date
- Jul 19, 2018
- Shares outstanding
- 136M, Jul 24, 2026
- Public float
- $900.00M, Nov 28, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-10 reverse, Jan 8, 2026; 1-for-10 reverse, Dec 2, 2025
- SEC CIK
- 1731348
- CUSIP
- 88688T209
- ISIN
- US88688T2096
- LEI
- 549300Y4V60733TO1478
- EIN
- 82-4310622
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Irwin D. Simon | President and CEO, Director | 1,309,031 |
| Mitchell Gendel | Global General Counsel | 148,644 |
| Denise M. Faltischek | Chief Strategy Officer | 199,489 |
| Carl A. Merton | Chief Financial Officer | 241,556 |
| Johann Michael Herhalt | Director | 195,561 |
| Thomas P. Looney | Director | 397,520 |
| Renah Persofsky | Director | 155,357 |
| Steven Michael Cohen | Director | 55,542 |
| David F. Clanachan | Director | 192,511 |
| David G. Hopkinson | Director | 43,104 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Mr.Simon | $22.16M | $18.59M | $3.43M | $3 | $16 |
| FY2025 Brendan Kennedy | $0 | $0 | $1.99M | $3 | $14 |
| FY2025 Irwin Simon | $10.30M | -$5.09M | $1.99M | $3 | $14 |
| FY2025 Mr.Simon | $10.30M | -$5.09M | $1.99M | $3 | $14 |
| FY2024 Brendan Kennedy | $0 | $0 | $2.06M | $11 | $21 |
| FY2024 Irwin Simon | $10.14M | $11.15M | $2.06M | $11 | $21 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of May 31, 2026, we have approximately 3,595 employees worldwide.”
Corporate history
Events identified from SEC filings